---
title: "CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283271354.md"
description: "CStone Pharmaceuticals (HK:2616) has unveiled three novel antibody-drug conjugate (ADC) candidates at the 2026 American Association for Cancer Research meeting. The lead candidate, CS5007, targets EGFR/HER3 and aims to overcome treatment resistance in oncology. Early data indicates CS5007 has superior plasma stability compared to existing ADCs, suggesting a favorable safety profile. CStone's ADC platform utilizes a hydrophilic linker and potent payload to enhance drug release and stability, reinforcing its position in the oncology market. The company focuses on innovative cancer therapies to improve patient outcomes."
datetime: "2026-04-20T00:08:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283271354.md)
  - [en](https://longbridge.com/en/news/283271354.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283271354.md)
---

# CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from CStone Pharmaceuticals ( (HK:2616) ).

CStone Pharmaceuticals has presented new preclinical data on three proprietary antibody-drug conjugates at the 2026 American Association for Cancer Research meeting, underscoring its push into next-generation oncology therapies. The candidates, CS5007 targeting EGFR/HER3, CS5006 targeting ITGB4, and CS5008 targeting DLL3/SSTR2, are all built on the company’s in-house ADC platform that uses a hydrophilic CSL20 linker and the potent exatecan payload to enhance stability and tumor-specific drug release.

Lead asset CS5007 is a bispecific ADC designed to bind both EGFR and HER3, addressing treatment resistance and tumor heterogeneity that limit current single-target EGFR drugs. Early in vitro data show CS5007 has superior plasma stability compared with an established benchmark ADC, with minimal free payload release over seven days, suggesting a potentially favorable safety profile and reinforcing CStone’s ambitions to strengthen its competitive position in the ADC segment of the oncology market.

**More about CStone Pharmaceuticals**

CStone Pharmaceuticals is a biopharmaceutical company focused on oncology, developing innovative cancer therapies using antibody-drug conjugate (ADC) technology. The group’s pipeline targets key oncogenic drivers in solid tumors, aiming to address resistance to existing treatments and improve outcomes for patients in global cancer markets.

**Average Trading Volume:** 14,368,076

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$14.39B

### Related Stocks

- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)

## Related News & Research

- [CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone](https://longbridge.com/en/news/286244356.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)
- [Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial](https://longbridge.com/en/news/286246864.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)